Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis
نویسندگان
چکیده
منابع مشابه
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?
Enormous progress has been made during the last 25 years in our understanding of the aetiopathogenesis of the anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV). This has led to improvements in early diagnosis, treatment and secondary prevention of these diseases. Nevertheless, there are still unmet needs in the AAV. With respect to diagnosis and follow-up, sensitive ...
متن کاملImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
BACKGROUND Rituximab (RTX), a B cell-depleting anti-CD20 monoclonal antibody, is approved for treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Low immunoglobulin (Ig) levels have been observed surrounding RTX treatment. The association between the degree of Ig deficiency and infection risk is unclear in AAV patients. METHODS AAV patients treated with RTX f...
متن کاملRituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
BACKGROUND AND OBJECTIVES Ongoing randomized trials seek to validate the efficacy of rituximab as an induction agent for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, no studies directly address the role of rituximab as maintenance therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This retrospective study reports the authors' experience with continuous...
متن کاملClinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
OBJECTIVE To evaluate whether the classification of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies) predicts treatment response. METHODS Treatment responses were assessed among patients enrolled in the Rituximab in ANCA-associated Vasculitis trial according to both A...
متن کاملC5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
INTRODUCTION The complement system is crucial for the development of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). In particular, C5a plays a central role. In this study, plasma and urinary levels of C5a as well as renal C5a receptors (CD88 and C5L2) expression were investigated in patients with AAV. METHODS Twenty-four patients with AAV in the active phase, 19 patie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical & Experimental Immunology
سال: 2011
ISSN: 0009-9104
DOI: 10.1111/j.1365-2249.2011.04363.x